FDA Grants Accelerated Approval to Gene Therapy for Recurrent Respiratory Papillomatosis
Source Summary
The FDA granted accelerated approval to doruxapapogene ralaplasmid and lalikinogene sifuplasmid (Voceryq) for adults with recurrent respiratory papillomatosis (RRP). The therapy is designed to reduce the frequency of surgical papilloma excisions in patients with this wart-like airway disease.
Why it matters
This accelerated approval provides the first gene therapy option for RRP patients, potentially reducing the burden of repeated surgical interventions required to manage the disease.
